Lipunova Nadezda, Wesselius Anke, Cheng Kar K, van Schooten Frederik J, Cazier Jean-Baptiste, Bryan Richard T, Zeegers Maurice P
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.
Department of Complex Genetics, Maastricht University, Maastricht, Netherlands.
Front Oncol. 2019 Oct 18;9:1082. doi: 10.3389/fonc.2019.01082. eCollection 2019.
Multiple studies have reported genetic associations with prognostic outcomes of urinary bladder cancer. However, the lack of replication of these associations prohibits establishing further evidence-based research directions. Moreover, there is a lack of independent bladder cancer patient samples that contain prognostic measures, making genetic replication analyses even more challenging. We have identified 1,534 eligible patients and used data on Hospital Episode Statistics in the UK Biobank to model variables of otherwise non-collected events on bladder cancer recurrence and progression. Data on survival was extracted from the Death Registry. We have used SNPTEST software to replicate previously reported genetic associations with bladder cancer recurrence ( = 69), progression ( = 23), survival ( = 53), and age at the time of diagnosis ( = 20). Using our algorithm, we have identified 618 recurrence and 58 UBC progression events. In total, there were 209 deaths (106 UBC-specific). In replication analyses, eight SNPs have reached nominal statistical significance ( < 0.05). Rs2042329 () for UBC recurrence; rs804256, rs4639, and rs804276 (in/close to ) for NMIBC recurrence; rs2293347 () for UBC OS; rs3756712 ( for NMIBC OS; rs2344673 ( for MIBC OS, and rs2297518 () for UBC progression. However, none have remained significant after adjustments for multiple comparisons. External replication in genetic epidemiology is an essential step to identify credible findings. In our study, we identify potential genetic targets of higher interest for UBC prognosis. In addition, we propose an algorithm for identifying UBC recurrence and progression using routinely-collected data on patient interventions.
多项研究报告了与膀胱癌预后结果的基因关联。然而,这些关联缺乏重复性,阻碍了进一步确立基于证据的研究方向。此外,缺乏包含预后指标的独立膀胱癌患者样本,使得基因重复性分析更具挑战性。我们确定了1534名符合条件的患者,并利用英国生物银行中医院事件统计数据对膀胱癌复发和进展的其他未收集事件的变量进行建模。生存数据从死亡登记处提取。我们使用SNPTEST软件对先前报道的与膀胱癌复发(n = 69)、进展(n = 23)、生存(n = 53)和诊断时年龄(n = 20)的基因关联进行重复性分析。使用我们的算法,我们确定了618例复发和58例尿路上皮癌进展事件。总共有209例死亡(106例为尿路上皮癌特异性死亡)。在重复性分析中,8个单核苷酸多态性(SNP)达到了名义统计学显著性(P < 0.05)。尿路上皮癌复发的rs2042329(P值);非肌层浸润性膀胱癌复发的rs804256、rs4639和rs804276(在基因内/靠近基因);尿路上皮癌总生存期的rs2293347(P值);非肌层浸润性膀胱癌总生存期的rs3756712(P值);肌层浸润性膀胱癌总生存期的rs2344673(P值),以及尿路上皮癌进展的rs2297518(P值)。然而,在进行多重比较校正后,没有一个仍然具有显著性。基因流行病学中的外部重复性是识别可靠研究结果的重要步骤。在我们的研究中,我们确定了尿路上皮癌预后中更具研究价值的潜在基因靶点。此外,我们提出了一种利用患者干预的常规收集数据来识别尿路上皮癌复发和进展的算法。